

APPLICANT FACSIMILE OF FORM PTO-1449
REV 7-80
PATENT AND TRADEMARK OFFICE

U.S. DEPARTMENT OF COMMERCE

ATTY DOCKET NO

SERIAL NO.

RPN-001CN

Not yet assigned

APPLICANT

Gray, G.S. et al.

FILING DATE

December 20, 2001

GROUP

LIST OF PUBLICATIONS CITED BY APPLICANT
(Use several sheets if necessary)

1036 U.S. PTO
10/27/03
12/20/01

ATTACH TO

11/2

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
hnn	A1	5,116,964	05/92	Capon et al.	536	27	
hrp	A2	5,428,130	06/95	Capon et al.	530	350	
lrx	A3	5,434,131	07/95	Linsley et al.	514	2	
wn	A4	6,130,316	10/00	Freeman et al.	530	350	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
AP	A5	WO 93/00431	01/93	PCT	—	—	
WM	A6	WO 95/33770	12/95	PCT	—	—	
LGW	A7	WO 96/31229	10/96	PCT	—	—	
ZN	A8	96305298	07/96	European	—	—	

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

LA	A9	Baliga, P. et al., "CTLA4Ig Prolongs Allograft Survival While Suppressing Cell-Mediated Immunity," <i>Transplantation</i> , Vol. 58, No. 10, 1082-1090 (1994);
	A10	Bolling, S. et al., "Inhibition of B7-Induced CD28 T-cell Activation with CTLA4Ig Prevents Cardiac Allograft Rejection: Evidence for Costimulation," <i>Transplantation</i> , Vol. 43, 413-415 (1992);
	A11	Burgess, W.H. et al., "Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-Binding Activities by Site-Directed Mutagenesis of a Single Lysine Residue," <i>The Journal of Cell Biology</i> , Vol. 111, pp. 2129-2138 (1990)
	A12	Canfield, S. and Morrison, S., "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH 2 Domain and is Modulated by the Hinge Region," <i>J. Exp. Med.</i> , Vol. 173, pp. 1483-1491 (1991);
	A13	Duncan, A. and Winter, G., "The Binding Site for Clq on IgG," <i>Nature</i> , Vol. 332, pp. 738-740 (1988);
↓	A14	Finck, Barbara et al., "Treatment of Murine Lupus with CTLA4Ig", <i>Science</i> , Vol. 265, pp. 1225-1227, 26 August (1994);
LAO	A15	Gillies et al., "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <i>Hum. Antibodies Hybridomas.</i> , Vol. 1, No. 1, pp. 47-54 (1990);

Examiner

Date Considered

5/16/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO RPN-001CN	SERIAL NO. Not yet assigned.
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Gray, G.S. et al.	10/27/03		
		FILING DATE December 20, 2001	GROUP		

U.S. PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

<i>LJN</i>	B1	Hakim, Frances, et al., "Acute Graft-Versus-Host Reaction Can Be Aborted by Blockade of Costimulatory Molecules", <i>The Journal of Immunology</i> , Vol. 155, No. 4, pp. 1757-1766 (1995);
<i>LJN</i>	B2	Lazar, E. et al., "Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities", <i>Molecular and Cellular Biology</i> , Vol. 8, pp. 1247-1252 (March, 1988)
	B3	Lenschow, D. et al., "Long-term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4Ig," <i>Science</i> , Vol. 257, pp. 789-792 (1992);
	B4	Lin, H. et al., "Long-term Acceptance of Major Histocompatibility Complex Mismatched Cardiac Allografts Induced by CTLA4Ig Plus Donor-specific Transfusion," <i>J. Exp. Med.</i> , Vol. 178, pp. 1801-1806 (1993);
	B5	Lin, M. C. et al., "Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon," <i>Molecular and Cellular Biology</i> , Vol. 8, pp. 1247-1252 (1988)
	B6	Lund, J. et al., "Human Fc γ RI and Fc γ RII Interact with Distinct but Overlapping Sites on Human IgG," <i>The Journal of Immunology</i> , Vol. 147, No. 8, pp. 2657-2662 (1991);
	B7	Pearson, T. et al., "Transplantation Tolerance Induced by CTLA4-Ig," <i>Transplantation</i> , Vol. 57, no. 12, pp. 1701-1706 (1994);
	B8	Schwartz, G. P. et al., "A Superactive Insulin: [B10-aspartic acid]insulin(human)," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 84, pp. 6508-6411 (1990)
<i>WJ</i>	B9	Steurer, Wolfgang et al., "Ex Vivo Coating of Islet Cell Allografts with Murine CTLA4/Fc Promotes Graft Tolerance", <i>The Journal of Immunology</i> , Vol. 155, No. 3, August 1, pp. 1165-1174 (1995);
<i>WJ</i>	B10	Tan, L. et al., "Influence of the Hinge Region on Complement Activation, C1q Binding, and Segmental Flexibility in Chimeric Human Immunoglobulins," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87, pp. 162-166 (1990).

Examiner  Date Considered *5/16/03*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.